Quarterly report pursuant to Section 13 or 15(d)

Fair Value Measurements - Additional Information (Detail)

v3.7.0.1
Fair Value Measurements - Additional Information (Detail) - USD ($)
 1 Months Ended 6 Months Ended
Mar. 17, 2014
Jun. 30, 2017
Dec. 31, 2016
Dec. 30, 2016
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Equity Method Investments $ 250,000 $ 300,000 $ 300,000  
Equity Method Investment, Ownership Percentage 35.00%      
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease), Total   500,000    
Investment Owned, at Fair Value   $ 3,406,000 $ 2,357,000  
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 4.02    
Equity Securities Called by Warrant       $ 10,000
Common Stock Par Or Stated Value Per Share   $ 0.001 $ 0.001  
Exercise Price Of Warrant Discount Percentage   33.00%    
Debt Conversion, Converted Instrument, Shares Issued   47,949    
Origo Acquisition Corporation [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Investment Owned, at Fair Value   $ 700,000    
Fair Value Assumptions Probability Of Business Combination   24.30%    
Working Capital Note Convertible To Equity   $ 300,000    
National Holdings Corporation [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Percentage of Outstanding Stock To Be Issued Upon Exercise of Warrants   43.40%    
Percentage of outstanding shares, Tendered   80.00%    
Class of Warrant or Right, Exercise Price of Warrants or Rights   $ 3.25    
Warrants Not Settleable in Cash, Fair Value Disclosure   $ 5,400,000    
Debt Instrument, Face Amount   $ 3,000,000    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   125,000    
Avenue Therapeutics, Inc. [Member] | IPO [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Stock Issued During Period, Value, New Issues   $ 37,900,000    
Stock Issued During Period, Shares, New Issues   6,300,000    
Common Stock Par Or Stated Value Per Share   $ 6.00    
Westpark [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Class of Warrant or Right, Exercise Price of Warrants or Rights   4.02    
Common Stock Par Or Stated Value Per Share   $ 6.00    
Class of Warrant or Right, Number of Securities Called by Warrants or Rights   2,488    
Exercise Price Of Warrant Discount Percentage   33.00%    
Binomial Lattice Model [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Business Acquisition, Share Price   $ 0.18    
Fair Value Assumptions, Expected Volatility Rate   0.24%    
Private Units [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Share Price   $ 9.73    
Argus Neurooptics Llc [Member] | Class A Preferred Stock [Member]        
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]        
Shares Received Under Purchase Agreement $ 13,409,962      
Percentage Of Shares Received Under Purchase Agreement 83.00%      
Preferred Units, Issued 16,091,954